Skip to content

Author

Kengo Nagashima

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

OA02.2. Survival Comparison in Patients With Pathological Complete Response Following Neoadjuvant Chemotherapy vs Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies In the treatment of esophageal squamous cell carcinoma (ESCC), previous studies have shown comparable overall survival (OS) between neoadjuvant chemotherapy (NAC) and neoadjuvant chemoradiotherapy (NACRT). While NACRT typically yields a higher patholog...

S. Matsuda, Jun Okui, Kengo Nagashima et al. · 0 citations
Open access Sep 2026

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1.

BACKGROUND The prognostic significance of PD-L1 expression in unresectable/recurrent gastric cancer treated by first-line chemotherapy without an immune checkpoint inhibitor (ICI) remains unclear. The phase III trial JCOG1013 demonstrated no overall survival (OS) or progression-free survival (PFS) benefit of docetaxel/...

H. Hirano, Yasuhide Yamada, Kengo Nagashima et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.